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ABSTRACT 
Introduction: Advances in cystic fibrosis (CF) 
therapy have resulted in improved survival and 
increasing treatment burden and costs. The 
economic impact of current treatment strategies 
for CF is poorly defined. 
Methods: The authors prospectively assessed 
direct medical costs (including hospitalizations, 
outpatient interventions, drugs, devices, dietetic 
products) in 165 consecutive CF patients (aged 
5–39 years) seen between March and July 2009. 
Results: The mean annual cost/patient increased 
with age and lung disease severity from
€4,164 in children aged ≤5 years to €30,123 
in patients aged >5 years with severe lung 
disease (forced expiratory volume in 1 second 
[FEV1] <40% of predicted). The increase in costs 
involved all items, with a progressive increase in 
cost attributed to hospitalizations. 
Conclusion: Treatment of CF is associated with 
relevant cost for the Italian National Healthcare 
Service. Costs of illness tend to increase 
progressively with age, suggesting that increasing
economic resources should be allocated to the 
treatment of CF, given the increasing number of 
patients surviving into adulthood. 
Keywords: Cystic fibrosis; Forced expiratory 
volume; Healthcare costs; Lung disease; 
Respiratory
INTRODUCTION
Cystic fibrosis (CF) is one of the most prevalent 
severe genetic diseases, with a high economic 
impact on healthcare systems due to its 
complexity [1]. The results of literature reviews, 
surveys, and registry analyses show a mean 
prevalence of 0.737/10,000 citizens in the 27 EU 
countries [2]. This prevalence is similar to the 
value of 0.680/10,000 citizens in Italy [3].
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CF is caused by a lack or dysfunction of 
cystic fibrosis transmembrane regulator (CFTR) 
protein, which acts mainly as a chloride channel 
at the apical membrane of epithelial cells, with 
consequent alteration of electrolyte transport, 
production of abnormally thick secretions, 
and progressive organ damage [4]. The clinical 
picture of CF is highly variable in terms of organ 
involvement (sweat glands, airways, pancreas, 
liver, gut, deferent ducts), age at diagnosis, 
and development of complications [5]. Lung 
disease is observed in over 90% of patients and 
represents the leading cause of morbidity and 
mortality [6].
Since its first description in 1938, CF has 
progressively evolved from a disease leading 
to death at a very young age due to respiratory 
failure and malnutrition, to a chronic condition 
with different manifestations also affecting 
adults [7]. 
Over the last 20 years, the therapeutic 
approach has markedly improved with the 
availability of new therapies for the prevention 
and treatment of respiratory infections (mucus 
active drugs, antibiotics) and closer attention to 
nutritional status and to complications associated 
with the disease (e.g., diabetes, liver disease, 
osteoporosis). While in the past antibiotics 
were mostly used to treat the exacerbations 
of CF-associated lung disease. More recently, 
the chronic use of antibiotics administered in 
aerosol formulation to suppress lung infection 
has become common practice in the routine care 
of CF and is strongly recommended by current 
CF therapeutic guidelines [8, 9].
The marked improvement in the therapeutic 
approach for CF has been paralleled by a 
progressive increase in mean life expectancy, 
which is now nearly 40 years in Western 
countries [10], with a consequential increase in 
the number of adult patients [11] who often have 
a more complex and severe form of the disease. 
Advances in therapy have been incremental and 
have resulted in an increase in direct medical 
costs and treatment burden [12].
Several studies designed to assess the costs 
of illness in patients with CF were carried out 
more than two decades ago [13–21]. These 
studies were reviewed by Krauth et al. [1] who 
highlighted the wide range of mean annual 
cost per patient (US$6,200–16,300, 1996 
rate), mainly due to differences in the clinical 
conditions of the patients considered, healthcare 
systems involved, and in the completeness of 
healthcare services and resource consumed. 
Healthcare costs were directly related to age and 
severity of the disease [1]. Most of these studies 
had major limitations, including the fact that 
only five were based on individual patient care 
data [14, 16, 18–20], whereas three were only 
aggregated expert cost estimations. 
More recently, Briesacher et al. [22] 
examined patterns of treatment in relation 
to whole costs using a nationwide research 
database of the healthcare claims of 
privately insured CF patients in the period 
2001–2007 [22]. This study documented a 
progressive increase in costs, from US$18,715 
in 2001 to US$29,718 in 2007 (+61%). This 
was largely influenced by more intensive 
monitoring of clinical status and lung function 
as well as by the increasing prevalence of 
respiratory pathogens (only 1.2% of the 
patients colonized by Pseudomonas aeruginosa
in 2001, compared with 63.2% in 2007), as 
indicated by the sharp increase in the use 
of oral (from 54.1% to 71.8%) and inhaled 
antibiotics (from 25.7% to 39.3%). Analysis by 
age confirmed the marked increase in costs of 
care for patients aged <10 years (from US$3,060 
to US$31,722) and for older patients, which 
more than doubled over the same period. 
As no study has been conducted in Italy, 
the aim of this economic evaluation was to 
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estimate the mean annual costs associated with 
the treatment of CF patients for the Italian 
National Healthcare Service (NHS). The authors 
therefore conducted a prospective, monocentric 
study to assess direct medical costs associated 
with CF treatment in Italy. All other costs (e.g., 
productivity losses, informal care, out-of-pocket 
expenses, etc) were not considered.
MATERIALS AND METHODS
Study Design
The authors carried out an observational, 
prospective, monocentric, prevalence-based 
study with a bottom-up design (consumption/
cost data of individual patients were determined 
and costs were aggregated over groups to arrive 
at total disease costs) [23]. 
The healthcare resources used by a sample of 
CF patients followed at the Lombardia Regional 
Cystic Fibrosis Reference Center (CFRRC) in 
Milan, Italy were assessed. All consecutive 
patients seen during an outpatient visit or who 
were hospitalized between March and July 2009 
were asked to participate in the study. 
Demographic and clinical data were 
recorded at baseline using a dedicated case 
report form (CRF). Data concerning the use of 
healthcare resources were collected in the CRF 
at each access to the CFRRC. Each patient was 
prospectively followed for 12 months. The 
number of hospitalizations and the length of 
stay were collected for each patient. For each 
drug, the dosage prescribed and the number 
of days on treatment per year for each patient 
was recorded. Single drugs were clustered into 
therapeutic groups. The type and number of 
each outpatient medical intervention, device, 
and dietetic product was recorded.
Enrolled patients were divided into two 
subgroups: Group 1 included patients 5 years 
of age or less (≤5 years) and Group 2 included 
patients more than 5 years of age (>5 years). At 
enrollment, patients in Group 2 were stratified 
according to severity of lung disease, based on 
forced expiratory volume in 1 second (FEV1) 
values: mild (FEV1 ≥70% of predicted), moderate 
(FEV1 ≥ 40–<70%) and severe (FEV1 <40%) [9]. 
In addition, the probability of 5-year survival 
was calculated for each patient in Group 2, 
according to the model proposed by Liou 
et al. [24, 25]. For this purpose, all variables 
included in the model were recorded in the CRF 
(age, gender, FEV1 %, weight Z-score, pancreatic 
status, diabetes, Staphylococcus aureus infection, 
Burkholderia cepacia complex infection, number 
of pulmonary exacerbations/year). Patients 
in Group 1 were not stratified for for lung 
disease severity, as reliable testing of respiratory 
function is not possible in children aged ≤5 years 
and there is no validated algorithm to estimate 
disease severity in this age group.
Annual Cost Analysis
The mean annual treatment cost was based on 
the overall healthcare resources (direct medical 
costs) used for each patient and reimbursed by 
the Italian NHS. Drug costs were obtained by the 
actual price paid by the Italian NHS, whereas 
hospitalization costs and costs associated 
with outpatient medical interventions were 
calculated according to reimbursement tariffs 
applied in Italy (reimbursed by Italian NHS). All 
costs denote 2009 prices.
A mean single annual cost was calculated for 
patients in Group 1. For patients in Group 2, three 
mean annual costs were calculated according to 
the lung disease severity class; a single mean 
annual cost was also estimated, adjusted for 
the actual distribution of the total number of 
patients followed-up at the CFRRC in each class 
of disease severity.
168 Adv Ther (2013)  30(2):165–75.
Statistical Analysis
Continuous data were expressed as means ± 
standard deviations or medians with ranges 
according to the distribution of the variables. 
Categorical data were expressed as numbers and 
percentages. The significance of the differences 
between groups was evaluated by the Mann-
Whitney test or the Kruskal-Wallis test (two-
tailed). A P value of <0.05 was considered 
statistically significant. All analyses were 
conducted using Microsoft® Excel® for Windows®
(Microsoft Corporation, Seattle, WA, USA) and 
SPSS® version 13.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
Patient Demographics and Disease Severity 
at Enrollment 
A total of 161 CF patients were enrolled; 
55 consecutive patients aged ≤5 years 
(Group 1) and 106 consecutive patients aged 
>5 years (Group 2). This number of patients 
represents approximately 30% of the CF 
population attending the CRRFC. Median age 
of the population enrolled was 11.6 years, with 
25% adults.
Table 1 summarizes the main demographics 
and clinical characteristics for each group. 
Pancreatic insufficiency was present in 72.7% 
of patients, and chronic P. aeruginosa infection 
was present in 9% of patients in Group 1 and in 
36% of those in Group 2.
In Group 2, a positive correlation between 
age and lung disease severity was documented 
(Fig. 1). Table 2 shows the distribution of 
patients in Group 2 by disease severity and the 
corresponding probability of 5-year survival that 
were inversely correlated. The difference in the 
probability of survival across severity groups was 
statistically significant (P < 0.001).
Table 1  Patient demographics and clinical characteristics 
  Group 1 Group 2 
  (≤5 years) (>5 years)
  (n = 55)  (n = 106)
Male, n (%) 25 (45) 58 (55)
Age (years)  
 Mean age ± SD 3 ± 2 17 ± 8
 Median age 2.8 16.3
 Range 0–5 5–39
Adults, n (%)  40 (37)
Pancreatic insuciency, n (%) 31 (56) 86 (81)
Diabetes, n (%) 0  20 (19)
Age at diagnosis (months)  
 Median  0.2 2.5
 Range 0–59 0–283
Pseudomonas aeruginosa  
 At least one positive culture 18 (33) 59 (56)
 Chronic infection 5 (9) 38 (36)
Other gram-bacteriaa 0 14 (13)
SD standard deviation 
a At least one positive culture for Burkholderia cepacia 



























Fig. 1  Lung disease severity (mild [FEV1 ≥70% of 
predicted], moderate [FEV1 ≤40 –<70%], and severe 
[FEV1 <40%]) by age categories in Group 2. FEV1 forced 
expiratory volume at 1 second
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Utilization of Healthcare Resources
Table 3 shows healthcare resources per patient 
used during the follow-up period. The mean 
number of medical interventions/patient/
year and the mean number and duration of 
hospitalizations/patient/year increased with 
age and disease severity. The mean number 
of hospitalizations/year/patient increased 
approximately ninefold in patients of Group 
2 with severe disease compared with those of 
Group 1 (P < 0.001) and a significantly longer 
duration of hospitalization was also documented 
(P < 0.001) (Table 3). 
Mean days on treatment/year/patient for 
different drug categories are shown in Table 3. 
Of note, the number of days on antibiotic 
treatment (by any route of administration) 
increased significantly with age and lung disease 
severity (P < 0.001).
Table 2  Probability of 5-year survival in cystic brosis 
patients included in Group 2, stratied by severity of lung 
disease
Class of severity N (%) Probability 
   of 5-year 
   survivala 
   (mean ± SD)
Mild (FEV1 ≥70%) 64 (61) 98 ± 3
Moderate (FEV1 ≤40–<70%) 29 (27) 87 ± 10
Severe (FEV1 <40%)  13 (12) 57 ± 28
Total 106 (100) 90 ± 17
P valueb  <0.001
FEV1 forced expiratory volume in 1 second 
a According to the Liou model [24] 
b Kruskal-Wallis test
Table 3  Utilization of healthcare resources 
  Group 1 Group 2 – mild Group 2 – moderate Group 2 – severe P valuea
  (n = 55)  (n = 64) (n = 29) (n = 13) 
Mean number of outpatient 26 27 34 36 0.002 
medical interventions/year/patient 
Mean number of hospitalizations/ 0.2 0.4 1.01 1.08 <0.001
year/patient 
Mean duration of hospitalization 3 5 14 32 <0.001 
(days)/year/patient 
Mean days on treatment/year/patient
Intravenous antibiotics 17 25 60 117 0.001
Inhaled antibiotics 38 133 208 311 <0.001
Oral antibiotics 20 76 179 240 <0.001
Bronchodilators 365 359 365 365 NS
Mucus active drugs 15 103 94 112 0.015
Vitamins 365 365 365 365 NS
Pancreatic enzymes 212 257 340 337 0.003
Antacids 86 88 142 84 NS
Bile acids 56 51 63 28 NS
Prokinetic agents 17 11 13 5 NS
Insulin  – 15 31 135 0.001
NS not signicant 
a Kruskal-Wallis Test
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Annual Cost of Treatment
The mean annual cost per patient increased 
with age and disease severity, with values 
ranging from €4,164 in Group 1 to €30,123 
in Group 2 with severe disease (Table 4). This 
increase in costs involved all items. The relative 
contribution of hospitalizations on the overall 
costs increased with severity of lung disease 
(Fig. 2). All differences in cost, between the two 
age groups and the subgroups with different 
disease severities, were statistically significant, 
with the only exception of costs related to 
devices, which was not significant (Table 4).
Table 5 shows the relative contribution of 
each drug category to the overall cost of drugs 
administered over the follow-up period. Inhaled 
antibiotics and mucus active drugs were the 
major drug categories affecting annual drug cost. 
The relative contribution of i.v. antibiotics and 
oral antimycotics on overall annual drug costs 
increased with age and disease severity, and 
was accompanied by a decrease in the relative 
contribution of bronchodilators, pancreatic 
enzymes, vitamins, and antacids (from 42.7% in 
Group 1 to 12.6% in Group 2 with severe lung 
disease).
Since patients with severe lung disease 
were more likely to be enrolled, due to a 
higher likelihood of access to the CFRRC 
compared with those with milder lung disease, 
we estimated a single mean annual cost for 
Group 2, adjusting for the actual distribution 
of all patients aged >5 years followed-up at the 
CRRFC (n = 338) in each class of disease severity. 
Actually, the frequency of severe lung disease 
was higher among the 106 patients enrolled 
in Group 2 (12.3%) than in all patients aged 
>5 years followed at our center (8.6%). A mean 
annual cost per patient in Group 2 was estimated 
at €15,137, which is more than three times the 
cost for patients of Group 1 (€4,164, P < 0.0001 
– Mann-Whitney Test).
Finally, the mean annual cost for adult 
patients (≥18 years) was 1.7 times higher than 
the cost for patients aged 5–18 years (€20,931 ± 
€14,903 vs. €12,378 ± €11,277, P = 0.004 Mann-
Whitney Test) and five times higher than for 
patients ≤5 years (€4,164 ± €4,065, P < 0.0001 
Mann-Whitney Test). 
Table 4  Mean annual cost (in Euro [€]) per patient stratied by age and disease severity
  Mean annual cost
  Total Drugs  Outpatient Hospitalizationsa  Devices  Dietetic 
    medical   product 
    interventions   
Group 1  4,164 2,704 728 524 164 44 
(n = 55)  
Group 2 – mild  12,186 9,625 797 1,495 168 102 
(n = 64) 
Group 2 – moderate  19,300 13,996 1,045 3,886 144 229 
(n = 29) 
Group 2 – severe  30,123 19,625 1,158 8,793 312 236 
(n = 13) 
P valueb <0.001 <0.001 0.002 <0.001 0.07 0.039
a Including costs for inpatient admissions and for day hospital 
b Kruskal-Wallis test
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DISCUSSION
In this prospective observational study, the cost 
analysis was based on individual patient care data 
from a population of 161 CF patients who were 
seen consecutively between March 2009 and July 
2009 at the CFRRC in Milan, Italy. According to 
a specific regulation in force in Italy [26], CF 
patients are followed in reference centers and all 
drugs must prescribed by the reference center. 
This system greatly favored a reliable monitoring 
of drug utilization in our study.
Table 5  Relative contribution of each drug category to the overall annual cost of drugsa 
  Group 1  Group 2 – mild Group 2 – moderate Group 2 – severe
  (n = 55) (n = 64) (n = 29) (n = 13)
Bronchodilators 16.6 4.6 3.2 2.3
Intravenous antibiotics 1.3 3.0 11.2 22.0
Oral antibiotics 1.2 1.8 2.0 2.6
Inhaled antibiotics 25.7 25.4 27.7 22.7
Mucus active drugs 24.8 46.3 29.2 24.8
Vitamins 5.4 1.6 1.2 0.8
Pancreatic enzymes 18.4 11.9 10.8 9.0
Antacids 2.3 0.8 0.9 0.5
Bile acids 1.9 0.5 0.4 0.1
Prokinetic agents 0.1 0.1 0 0
Oral antimycotic 0 1.8 9.6 12.2
Insulin 0 1.0 1.2 2.1
a Results are presented as percentage of total annual cost of drugs
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Fig. 2  Relative contribution of dierent items of health cost stratied by age and lung disease severity 
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Only direct medical costs were considered, 
including inpatient and outpatient costs and 
costs associated with drugs, dietetic products, 
and device prescriptions. The Italian NHS 
perspective was considered.
The results of this study clearly show that 
mean treatment costs increase with disease 
severity, assessed by FEV1 categories and 
confirmed by the Liou 5-year survival model [24]. 
Treating a patient with severe lung disease costs 
about 2.5 times the costs of treating a patient 
with mild disease (€30,123 vs. €12,186) (P < 
0.001); this increase was determined mainly 
by hospitalization (+488%), followed by drugs 
(+104%), and outpatient medical interventions 
(+45%). Similar findings were previously 
reported by Lieu et al. [20] who also classified 
disease severity according to FEV1 values. These 
data confirm the importance of disease severity 
as a cost driver. 
The results also demonstrate a direct 
correlation between treatment cost and age; 
the ratio between the mean cost of illness for 
adults and children was 3.4 in the current 
study, which is higher than previously reported 
(2.0–2.3) [14, 27]. It cannot be excluded 
that the lower economic resources spent for 
pediatric patients may be attributed to the 
aggressive therapeutic approach, which is now 
recommended beginning at the time of diagnosis 
and is associated with slower progression of lung 
disease and a reduced number of hospitalizations 
in childhood [28]. 
Indeed, the cost for hospitalization was 
17-fold higher in patients in Group 2 with severe 
lung disease compared with patients in Group 1. 
The direct medical costs of illness estimated 
in the present study are slightly lower than 
those reported in two recent studies. In a 
multicenter study involving seven CF centers in 
Germany, Eidt-Koch et al. [29] analyzed the cost 
of pharmacological therapy in 301 patients with 
a mean age of 19.9 years. In this study, the mean 
annual cost per patient was €21,603. Medication 
costs were higher in older patients, probably due 
to the higher rate of bacterial colonization in 
adults than in children (up to 95% vs. 67.4% 
of patients aged <17 years). The lower costs of 
illness found in this study may be related to the 
much lower rate of gram-negative chronic lung 
infection seen in our population (26.7%). In 
addition, drug costs in Germany are generally 
higher than in Italy. For aerolized antibiotics, 
the cost for tobramycin during the study period 
was €59.16/unit in Germany compared with 
€50/unit in Italy; colistin, the most frequently 
prescribed antibiotic for inhalation in our 
patients (86%), was €17.47/unit in Germany, 
which is around three times more expensive 
than in Italy. Most of the other CF-related 
therapies (pancreatin, azithromycin, itraconazol) 
were twice as expensive in Germany. 
Another observational, prospective study 
analyzed the cost of illness in 352 patients (mean 
age 14.6 years) with mild lung disease from 61 US 
centers during a 48-week clinical trial (TIGER-1) 
investigating the efficacy of denufosol versus 
placebo [30]. The mean cost per patient due 
to hospitalization was US$4,367, and the cost 
due to pharmacological therapy was US$33,394; 
these costs accounted for 11.3% and 86.7% of 
the total costs, respectively. Expressed in euros, 
this would correspond to €29,610 as compared 
to a cost of €12,021 observed in patients with 
mild severity of the disease. However, this study 
also considered the costs of healthcare providers 
and indirect costs (number of days missed from 
work or school) that were not considered in this 
study. In addition, despite the fact that patients 
in the TIGER-1 trial had a nearly normal lung 
function (FEV1 >75% of predicted), more than 
one-third (37%) were on long-term inhaled 
antibiotics (mostly tobramycin). This is a higher 
percentage when compared with patients in 
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this study with the same clinical characteristics 
(14%) who were mostly receiving the much 
cheaper colistin. 
The major limitation of the current study 
is that it was carried out in a single center, 
enrolling a relatively limited sample size, with 
a predominance of pediatric patients (only 
25% of the patients were adults) who are less 
frequently colonized by respiratory pathogens. 
This may have caused an underestimation 
of the mean cost per patient that may not 
be fully representative of the average costs 
sustained by CF centers in Western countries. 
In conclusion, the results show that the 
treatment of CF represents a major cost for the 
Italian healthcare system [1], that may increase 
further with the forthcoming availability of 
new and expensive drugs targeted to correct 
the basic defect underlying CF [31, 32]. Disease 
costs tend to increase progressively with age, 
suggesting that increasing economic resources 
should be allocated to the treatment of CF given 
the increasing number of patients surviving 
into adulthood. Despite the large economic 
resources necessary for providing CF patients 
with treatment strategies that have the potential 
to increase life expectancy and improve quality 
of life, suboptimal treatment may lead to a 
significant increase in costs for the healthcare 
system.
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